By Tom Zanki ( September 29, 2020, 5:48 PM EDT) -- Danish biotechnology firm Orphazyme raised $84 million on Tuesday through a U.S. initial public offering and private placement in order to fund a therapy for rare neurodegenerative diseases, advised by Cooley LLP and underwriters counsel Shearman & Sterling LLP....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.